Clinical trials: Esophagogastric Cancer
Gastric Cancer, Reflux Esophagitis
Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy
In the past years, the adenocarcinoma of the esophagogastric junction (AEG) has been increasing obviously in China. It may be caused by the reason of increased body weight, alcohol consumption, gastroesophageal reflux disease and…
- Trial name
- NCT04657848
- Testing
- proximal gastrectomy combined with Cheng's Giraffe reconstruction
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
CAR T-Cell Therapy
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects.
- Trial name
- NCT05277987
- Testing
- HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T Cells)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Fifth People's Hospital
Esophageal Neoplasms, Esophagectomy
Effect of Neck Flexion on Esophagogastric Anastomotic Leakage After MIE
Esophageal cancer (EC) is the eighth most common cancer and the sixth leading cause of cancer deaths worldwide. Minimally invasive esophagectomy (MIE) is regarded as a safe and effective management for resectable EC.
- Conditions
- Esophageal Neoplasms, Esophagectomy, Anastomotic Leak
- Trial name
- NCT02418052
- Testing
- neck flexion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Gastroesophageal Junction Adenocarcinoma
Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction
Stage I：preoperative therapy Capecitabine plus oxaliplatin with concurrent radiotherapy is superior to surgery alone ; Stage II: Perioperative therapy Perioperative Capecitabine plus oxaliplatin with Concurrent radiotherapy is…
- Trial name
- A-C (NCT01962246)
- Testing
- Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent radiotherapy
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Hebei Medical University
Esophageal Cancer, Esophagogastric Junction Cancer
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
- Trial name
- CRATER (NCT05245760)
- Testing
- Intravenous Tislelizumab, Chemotherapy, Fractionated radiation
- Where
- United States
- Sponsor
- Zhonglin Hao
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
IMAGINE is a Phase II, randomized, two-arm, chemotherapy controlled modular trial in subjects with histologically confirmed, resectable gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (AEG).
- Trial name
- IMAGINE (NCT04062656)
- Testing
- Nivolumab, relatlimab, Oxaliplatin
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- University Hospital, Essen
Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Adenocarcinoma, Resectable Esophageal Cancer
- Trial name
- HEPATOXALI (NCT06649474)
- Testing
- assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Esophageal Cancer
Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX
Determine the safety and efficacy of novel suture in esophageal anastomosis. Specific Aims: 1) Determine the safety of using STRATAFIX suture in esophagogastric anastomosis by measuring anastomotic leak rate; and 2) Determine…
- Trial name
- NCT02609425
- Testing
- Stratafix PGA Suture
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
This is a single-arm, open-label, clinical study to evaluate the safety of HER2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with HER2/neu overexpressing gastric or gastroesophageal…
- Trial name
- NCT05315830
- Testing
- HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Gastroesophageal Cancer, Immune Checkpoint Inhibition
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
- Trial name
- REACTION (NCT03610711)
- Testing
- Nivolumab, Relatlimab
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms, Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to determine a dose for future development and to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy profiles of JNJ-42756493 in Japanese and other Asian patients with advanced or…
- Conditions
- Neoplasms, Lymphoma, Adenocarcinoma, Esophagogastric Junction
- Trial name
- NCT01962532
- Testing
- Part 1: JNJ-42756493, Part 2: JNJ-42756493
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Adenocarcinoma of the Esophagus or Esophagogastric Junction
Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.
In this trial, patients with histologically proven adenocarcinoma of the esophagus or esophagogastric junction noneligible for surgery or chemoradiation with curative intent will be included.
- Trial name
- PALAESTRA (NCT02241499)
- Testing
- Radiation therapy, Oxaliplatin and fluorouracil.
- Where
- Sweden
- Volunteers
- 29 people
- Sponsor
- Lund University Hospital
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric…
- Trial name
- NCT01095120
- Testing
- Tesetaxel
- Where
- 4 sites in United States, South Korea
- Volunteers
- 27 people
- Sponsor
- Genta Incorporated
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of…
- Trial name
- NCT07026149
- Testing
- Apatinib+Camrelizumab+SOX, Preoperative Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Oesophageal Cancer, Gastric Cancer
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma…
- Conditions
- Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP
- Trial name
- FAPIDO (NCT06782412)
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- 3 sites in Belgium
- Volunteers
- 109 people
- Sponsor
- KU Leuven
Carcinomas of the Esophagogastric Junction
Esophagogastrectomy Versus Extended Gastrectomy in AEG II
Comparison of the oncological outcome of patients who underwent esophagogastrectomy versus extended gastrectomy due to carcinomas of the esophagogastric junction (Siewert type II)
- Trial name
- AEG-II-EG (NCT02302118)
- Testing
- Esophagogastrectomy
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Gastric Adenocarcinoma, Pancreatic Cancer
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic…
- Conditions
- Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04581473
- Testing
- CT041 autologous CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
- Where
- 24 sites in China
- Volunteers
- 192 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Patient Reported Outcome Measures, Colorectal Cancer
Predicting Disease Progression and/or Recurrence in Cancer
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer…
- Conditions
- Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT04776837
- Testing
- Observational Cohort
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Massachusetts General Hospital
Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
- Trial name
- NCT07556640
- Testing
- LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital